Skip to content
Immuno-Oncology In Vitro Solutions
We deliver customizable assays tailored to your goals, using co-culture systems, tumor spheroids, and immune subsets to assess immune activation, tumor killing, and immunogenicity with translational relevance and cost efficiency.
Advance Discovery with Custom Immuno-Oncology Assays
We start with either whole blood or established cell sources and integrate imaging, flow cytometry, and biophysical approaches to interrogate immune activation, modulation, and tumor killing through complementary, high-content workflows.
Ichor Offers Comprehensive Immuno-Oncology Solutions
Hematopoietic Stem Cell
Model immune development and differentiation with hematopoietic stem cell–based systems, using CFU and proliferation assays to assess lineage commitment, expansion, and therapeutic modulation under your biologics.
Immune Cell Activation
Interrogate immune function with tailored assays, including dendritic cell activation, macrophage polarization, and neutrophil adherence, to capture diverse activation and modulation profiles.
Immune Cell Migration
Assess chemotaxis, transmigration, and infiltration dynamics using transwell systems, 3D matrices, and live-cell imaging.
Tumor Sensitization
Evaluate tumor response to small molecules or biologics that modulate immune pathways, enabling rational combination strategies and improved therapeutic outcomes.
T cell killing
Quantify antigen-specific cytotoxicity and checkpoint modulation using real-time imaging, flow cytometry, and functional co-culture in highly controlled systems.
Antibody-Drug Conjugates (ADCs)
As a rapidly expanding area of oncology research, ADCs combine immune targeting with potent payloads. We evaluate ADC efficacy by integrating immune engagement, tumor killing, and payload potency in translational in vitro models.
Tailored T Cell Migration Assay
Migration assays are pivotal not only for demonstrating immune infiltration in oncology but also for de-risking safety by ensuring candidates do not trigger unwanted trafficking. At Ichor, we go beyond rigid, one-size-fits-all readouts by optimizing assay ranges and interpreting results in the context of your project goals—recognizing that the same readout can mean very different things depending on therapeutic intent. By benchmarking across immune-relevant T cell migration assay with Jurkat and CCRF-CEM, and integrating transwell systems, 3D matrices, and live-cell imaging, we deliver data that reflects biology, not just endpoints to help you evaluate both therapeutic potential and immunotoxicity risk.
Antigen Presentation with T cell Killing Readouts
Primary Dendritic Cell Stimulation
Dendritic cells are a focus of many immuno-oncology studies but are scarce in blood and traditionally difficult to scale using classical flow cytometry. Our miniaturized platform enables higher-throughput DC treatment and stimulation of T cells using significantly fewer cells, providing clients with robust and translational data from otherwise challenging assays.
T cell-Mediated Tumor Killing in Real-Time
DC-primed CD8 T cells are co-cultured with diverse cancer cell lines to assess tumor cell apoptosis and immune activation. Killing is tracked in real time using a green apoptosis reagent, with benchmarking against tumor antigen–specific controls and reference standards. Our platform combines kinetic live-cell imaging with orthogonal flow cytometry readouts, offering flexible, biologically relevant insights into T cell–mediated cytotoxicity.
Frequently Asked Questions
We source primary cells from whole blood or leukopak in addition to established immune cell lines to test against a broad panel of tumor cell lines to ensure assays reflect your therapeutic context.
Ichor does both. We work closely with you to identify and implement the most appropriate assay controls, ensuring your therapy is benchmarked against relevant standards and yielding meaningful, interpretable data.
Our miniaturized, high-content platforms require fewer primary cells, provide kinetic data, and deliver higher throughput, making challenging assays like DC–T cell co-cultures more feasible and scalable for faster iterative cycles.